Research Programs
The AIEDD CRC proposes four interconnected and synergistic research programs (RPs) designed to drive innovation. The RPs will adopt a comprehensive patient-centric framework to drug discovery, integrating patient data and outcomes to guide more informed and clinically relevant decision making throughout the development process.
-
RP1 will develop new and extend known, AI-enhanced -omics interrogation technologies to discover and validate novel targets.
-
Evaluate/re-evaluate reported targets and examine validity.
-
Use AI-enabled technologies to identify molecular probes (e.g. new or existing chemical matter) for those targets, likely to elicit the required response.
-
-
RP2 will develop and use human-originated, disease-relevant models and platforms (e.g. 3D cell cultures, organoids) to interrogate therapeutic responses to novel drugs/targets identified in RP1, at a local/micro-level.
-
Use AI to develop validation methods such as assays, e.g., using the molecular probes from RP1.
-
Use AI to create digital models of disease to predict therapeutic response, incorporating PK/PD considerations.
-
-
RP4 will leverage findings from RP1-3 to inform drug development.
-
Apply tools from RP1 to discover and/or optimise new chemical material.
-
Develop AI tools for population-level patient stratification based on disease subtypes or drug responsiveness, to improve clinical trial design and success rate.
-
Use AI approaches to identify potential ‘combination therapies’.
-
-
RP3 will Use AI-enhanced technologies to integrate and interrogate -omics and other biological datasets to better predict how a drug candidate will behave in the whole patient.
-
Build complex systems biology models to predict drug performance and limit off-target effects.
-
Provide relevance of drug mechanism on action and inform property optimization requirements.
-